GailJRobozMD

Hematologic Oncology

Associate Professor, Medicine, Weill Cornell Medical College

Overview of Dr. Roboz

Dr. Gail Roboz is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, New York-Presbyterian Hospital, New York-Presbyterian Hospital, NewYork-Presbyterian/Columbia University Irving Medical Center, and Long Island Jewish Medical Center. She received her medical degree from Icahn School of Medicine at Mount Sinai and has been in practice 23 years. Dr. Roboz accepts several types of health insurance, listed below. She is one of 102 doctors at Long Island Jewish Medical Center and one of 379 doctors at New York-Presbyterian Hospital who specialize in Oncology. She has more than 100 publications and over 500 citings.

Office
525 E 68th St
New York, NY 10065
Book by Phone+1(814) 414-4401

Fax+1 212-746-3305

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 1997 - 2000
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1995 - 1997
Beth Israel Deaconess Medical CenterInternship, Internal Medicine, 1994 - 1995
Icahn School of Medicine at Mount SinaiClass of 1994

Certifications & Licensure

NY State Medical License 1995 - 2026
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top Doctors: New York Metro Area Castle Connolly, 2012-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Super Doctor SuperDoctors.com

Clinical Trials

Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML Start of enrollment: 2003 Sep 17
Completed
Phase 1, Phase 2
Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis Start of enrollment: 2008 Feb 29
Completed
Early Phase 1
Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML) Start of enrollment: 2011 Nov 21
Completed
Phase 1, Phase 2
Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML) Start of enrollment: 2011 Jun 17
Completed
Phase 1
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy Start of enrollment: 2011 Jul 01
Completed
Phase 2
Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia Start of enrollment: 2011 Nov 16
Completed
Phase 2
A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL Start of enrollment: 2012 Mar 01
Terminated
Phase 3
A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission Start of enrollment: 2012 Jul 01
Completed
Phase 1
A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
Completed
Phase 2
Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis Start of enrollment: 2013 Jan 01
Terminated
Phase 2
Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine Start of enrollment: 2013 Aug 01
Completed
Phase 3
Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox. Start of enrollment: 2014 Sep 11
Terminated
Phase 2
Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients Start of enrollment: 2021 Nov 09
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML Start of enrollment: 2016 May 01
Recruiting
Phase 2
Roles: Principal Investigator, Contact
A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) Start of enrollment: 2022 Aug 16
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

48 citations
Practical Implications of the 2016 Revision of the World Health Organization Classification of Lymphoid and Myeloid Neoplasms and Acute Leukemia.
John P. Leonard, Peter Martin, Gail J. Roboz
Journal of Clinical Oncology. 2017-06-27
144 citations
Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis
Ayalew Tefferi, Srdan Verstovsek, Giovanni Barosi, Francesco Passamonti, Gail J. Roboz
Journal of Clinical Oncology. 2009-09-20
93 citations
Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies
Michael J. Satlin, David P. Calfee, Liang Chen, Kathy A. Fauntleroy, Stephen J. Wilson
Leukemia & Lymphoma. 2013-04-01

Journal Articles

Somatic Mutations Precede Acute Myeloid Leukemia Years Before Diagnosis
Sangmin Lee, Pinkal Desai, Gail J Roboz, Ellen K Ritchie, Nature
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine

Abstracts/Posters

CPX-351 As First Intensive Therapy for Elderly Patients with AML
Gail J. Roboz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ...
Gail J. Roboz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration t...
Gail J. Roboz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based TherapiesClinically Relevant Abstract
Gail J. Roboz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS)
Gail J. Roboz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best...
Gail J. Roboz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Te...
Gail J. Roboz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes
Gail J. Roboz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Antecedent Clonal Hematopoesis and Risk of and Mortality after Solid and Hematological Malignancies: Analyses from the Women's Health Initiative Study
Gail J. Roboz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Management of Neutropenia during Venetoclax-Based Combination Treatment in Patients with Newly Diagnosed Acute Myeloid Leukemia
Gail J. Roboz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
PTPN11 Mutated Acute Myeloid Leukemia (AML) Features an Abundant Epichaperome Network and Is Sensitive to the Epichaperome Inhibitor PU-H71
Gail J. Roboz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)Clinicall...
Gail J. Roboz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
Gail J. Roboz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase II Trial of SGI-110 (Guadecitabine) in Philadelphia Negative Myeloproliferative Neoplasms
Gail J. Roboz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Changes in Gut Microbial Diversity and Correlations with Clinical Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Receiving Intensive Chemotherapy
Gail J. Roboz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial
Gail J. Roboz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Patient Derived Xenografts (PDX) Recapitulate Ruxolitinib Clinical Trial Responses and Identify a Novel Combination Therapy for Chronic Myelomonocytic Leukemia (CMML)
Gail J. Roboz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients wit...
Gail J. Roboz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Incidence of Serious Adverse Events, Pneumonitis, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphom...
Gail J. Roboz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Minimal Residual Disease in Hematologic Malignancies: Testing Considerations and Challenges
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Na¥ve (TN) AML Unfit for Intensive Chemothe...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Ivosidenib (IVO; AG-120) in IDH1-mutant newly-diagnosed acute myeloid leukemia (ND AML): Updated results from a phase 1 study.
2019 ASCO Annual Meeting - 6/1/2019
Does Presence of Persistent Molecular Mutations Matter in AML Patients Undergoing Allogeneic Stem Cell Transplant?
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Final Safety and Efficacy Results from the CPX-351 Early Access Program (EAP) for Older Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)Clinicall...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Targeting the Epichaperome As an Effective Precision Medicine Approach in a Novel PML-SYK Fusion Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Interim Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients with Untreated Acute Myeloid Leukemia (AML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete R...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase 2 Study of Actinium-225 (225Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediat...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Focus on AML: Clinical Practice Today
60th American Society of Hematology Annual Meeting - 11/30/2018
Join now to see all

Press Mentions

MRD and Relapse in Patients with AMLAugust 17th, 2022
Treating Older AML Patients and Managing Unique ToxicitiesJuly 20th, 2022
Adverse-Risk Acute Myeloid LeukemiaJune 16th, 2022
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS California CaliforniaCare HMO
BCBS California PowerSelect HMO
BCBS California PPO
BCBS Illinois PPO
Blue Shield California HMO
Blue Shield California PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPO
Great West PPO
Health Net California Large Group PPO
Health Net HMO - Employer Group
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
MagnaCare PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
Pacificare HMO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
WEA Trust Preferred Provider Plan - Trust Pref
Please verify your coverage with the provider's office directly when scheduling an appointment